Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Increases NCI s Access to Its Microarray Technology

NEW YORK (GenomeWeb News) - Agilent Technologies has expanded the National Cancer Institute's access to its microarray technology program, the company said today.

 

Under the program, NCI extramural researchers can obtain Agilent's microarray technology -- including reagents, catalogs and custom microarrays, instrumentation, and software -- for comparative genomic hybridization, location analysis, and gene expression.

 

The NCI funds approximately 4,500 research grants each year.

 

Researchers realize gene-expression data alone is not enough in cancer research, and that complementary microarray applications are necessary, the company said.

 

Agilent will offer researchers promotional pricing, the company said.

 

Separately today, Agilent said it wrapped up the sale of its semiconductor products business to Kohlberg Kravis Roberts and Silver Lake Partners for $2.66 billion.

 

Originally scheduled to complete on Oct. 31, the divesture was delayed to December to "provide a seamless transition," the company said.

 

The divestiture includes 6,500 employees and operations in Asia, the United States and Europe.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.